Goldman Sachs
CADX

Goldman Sachs’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Goldman Sachs’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-14,364
Closed -$130K – 7099
2013
Q4 		$130K Sell
14,364
-21,252
-60% -$153K ﹤0.01% 6177
2013
Q3 		$224K Buy
35,616
+18,774
+111% +$119K ﹤0.01% 5781
2013
Q2 		$115K Buy
+16,842
New +$117K ﹤0.01% 5834

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Goldman Sachs's CADX Position: Q1 2014 in Review

Goldman Sachs sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 14,364 shares — an estimated $130K sold.

Goldman Sachs first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $224K in Q3 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Goldman Sachs reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Goldman Sachs sold 14,364 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $130K.
  • Goldman Sachs first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Goldman Sachs's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $224K in Q3 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Goldman Sachs's 13F filing for Q1 2014, filed 15 May 2014.